Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines

Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines

(2017) Elizabeth Larocque et al.   Future Medicinal Chemistry

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

(2017) Masamichi Mori et al.   INVESTIGATIONAL NEW DRUGS

Opportunities and challenges in phenotypic drug discovery: an industry perspective

(2017) John G. Moffat et al.   NATURE REVIEWS DRUG DISCOVERY

Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach

(2017) Xiaochu Ma et al.   ACS Medicinal Chemistry Letters

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

(2016) Jason Gotlib et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug resistance in cancer: molecular evolution and compensatory proliferation

(2016) Ran Friedman   Oncotarget

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

(2015) C C Smith et al.   LEUKEMIA

FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia

(2015) Michael R. Grunwald et al.   SEMINARS IN HEMATOLOGY

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia

(2015) Houda Alachkar et al.   Oncotarget

Inhibition of c-Kit by tyrosine kinase inhibitors

(2014) A. Galanis et al.   HAEMATOLOGICA

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

(2014) K. Keegan et al.   MOLECULAR CANCER THERAPEUTICS

TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis

(2014) Y. Matsuo et al.   Science Translational Medicine

AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia

(2013) Anna Eriksson et al.   BIOCHEMICAL PHARMACOLOGY

Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia

(2013) E. I. Zimmerman et al.   BLOOD

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

(2013) A. Galanis et al.   BLOOD

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of FLT3 Kinase as an AML Therapy Target

(2012) Michal Beffinger et al.   CURRENT PHARMACEUTICAL DESIGN

FLT3 inhibitors: a story of the old and the new

(2011) Amir Fathi et al.   CURRENT OPINION IN HEMATOLOGY